AU2021222342A1 - Method for treating chronic graft versus host disease - Google Patents

Method for treating chronic graft versus host disease Download PDF

Info

Publication number
AU2021222342A1
AU2021222342A1 AU2021222342A AU2021222342A AU2021222342A1 AU 2021222342 A1 AU2021222342 A1 AU 2021222342A1 AU 2021222342 A AU2021222342 A AU 2021222342A AU 2021222342 A AU2021222342 A AU 2021222342A AU 2021222342 A1 AU2021222342 A1 AU 2021222342A1
Authority
AU
Australia
Prior art keywords
cells
score
reduction
point
mlpscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021222342A
Other languages
English (en)
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2021222342A1 publication Critical patent/AU2021222342A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021222342A 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease Pending AU2021222342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
AU2020900472 2020-02-19
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (1)

Publication Number Publication Date
AU2021222342A1 true AU2021222342A1 (en) 2022-09-15

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021222342A Pending AU2021222342A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Country Status (9)

Country Link
US (1) US20230097931A1 (cg-RX-API-DMAC7.html)
EP (1) EP4106776A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023513847A (cg-RX-API-DMAC7.html)
KR (1) KR20220143092A (cg-RX-API-DMAC7.html)
CN (1) CN115361960A (cg-RX-API-DMAC7.html)
AU (1) AU2021222342A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016448A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168330A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021165420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370930A (zh) 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
AU2024218133A1 (en) * 2023-02-08 2025-09-18 Mesoblast International Sarl Potency assay and manufacturing method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
SG193888A1 (en) * 2008-09-03 2013-10-30 Mesoblast Inc Expansion of haemopoietic precursors
WO2012048093A2 (en) * 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2015061839A1 (en) * 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Also Published As

Publication number Publication date
BR112022016448A2 (pt) 2022-11-29
JP2023513847A (ja) 2023-04-03
KR20220143092A (ko) 2022-10-24
EP4106776A1 (en) 2022-12-28
WO2021165420A1 (en) 2021-08-26
CN115361960A (zh) 2022-11-18
US20230097931A1 (en) 2023-03-30
CA3168330A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
EP4106776A1 (en) Method for treating chronic graft versus host disease
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230104108A1 (en) Method for treating inflammatory bowel disease ii
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20250032552A1 (en) Method of treating severe graft versus host disease
EP4192482A1 (en) A composition comprising mesenchymal precursor or stem cells and their use
WO2022132986A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
CA3260880A1 (en) CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
WO2025046491A1 (en) Third line treatment for gvhd
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure